Status:
UNKNOWN
The Role of EEG in Identifying Cognitive Changes in Parkinson's Disease
Lead Sponsor:
Federal University of Paraíba
Conditions:
Parkinson Disease
Cognition Disorder
Eligibility:
All Genders
40-80 years
Phase:
NA
Brief Summary
This study is a group controlled clinical trial. Parallel study, patients aged 40-80 years, with Parkinson disease. Twelve sessions, three times a week, for 30 minutes. Training will consist of Transc...
Detailed Description
Background: Parkinson disease (PD) is one of the most common age-related brain disorders. PD is defined primarily as a movement disorder, with the typical symptoms being resting tremor, rigidity, brad...
Eligibility Criteria
Inclusion
- being diagnosed with idiopathic Parkinson's disease by a neurologist based on definitive evidence of responsiveness to levodopa at the start of the disease and the history of progressive hypokinesia with asymmetric onset. PD will be diagnosed based on Parkinson's Disease Society Brain Bank (PDSBB) criteria, as described in Hughes et al. (1992)
- Age between 40 and 70 years, with no distinction for sex, schooling level or other sociodemographic characteristics;
- disease staging between 1.5 and 3, according to the modified Hoehn and Yahr scale (Hoehn and Yahr, 1998);
- undergoing regular pharmacological treatment with levodopa (equivalent dose \> 300 mg) or taking antiparkinsonian medication, such as anticholinergics, selegiline, dopamine agonists, and COMT (catechol-O-methyl transferase) inhibitors for at least 4 weeks prior intervention;
- score of more than 24 points on the Mini-Mental State Examination (Folstein et al., 1975);
- not exhibiting other associated neurological diseases; and
- no musculoskeletal and/or cardiorespiratory changes that could compromise gait.
Exclusion
- diagnosis of atypical Parkinson's disease;
- neuropsychiatric comorbidities;
- convulsions, metal clips and/or pacemaker;
- deep brain stimulation implant;
- history of epilepsy; neurosurgery;
- traumatic brain injury;
- alcohol abuse or drug dependency;
- associated diseases of the peripheral or central nervous system;
- undergoing physical therapy at another location;
- inability to walk 10 meters;
- presence of important dyskinesia that prevents the participant from sitting in a chair;
- abnormal and persistent increase in systemic blood pressure before or during training, after three measurements taken 5 min apart-Cut-off: systolic blood pressure ≥ 140 mm Hg and/or diastolic ≥ 90 mm Hg (Malachias et al., 2016);
- not understanding any of the training protocol stages; chemical scalp treatment within the previous 30 days, and experiencing severe pain and/or discomfort that precludes performing the proposed activities.
Key Trial Info
Start Date :
August 2 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2024
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT06145776
Start Date
August 2 2023
End Date
April 1 2024
Last Update
December 1 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Federal University of Paraiba
João Pessoa, Paraíba, Brazil, 51051900
2
Aging and Neuroscience Studies Laboratory
João Pessoa, Brazil